A Dexcom spokeswoman said there are already 20,000 Medicare patients in the pipeline with almost no advertisement of the policy change.
After hitting a few snags and finding a partner to create the bundle needed for Medicare shipping requirements, Dexcom is now shipping the Dexcom G5 to beneficiaries who meet criteria for coverage for continuous glucose monitoring (CGM).
A 2-step process over the past year allowed Medicare patients to gain access to CGM, after years of work by advocacy groups, physicians, patients, and members of Congress. First, FDA updated the Dexcom G5 approval to include dosing, which paved the way for CMS to add the Dexcom G5 to its schedule of durable medical equipment. Dexcom’s G5 is the only CGM system approved for therapeutic use, which means patients need the system to maintain glycemic control.
It wasn’t that easy at first. Dexcom had to find a partner in Ascensia, which provides the blood glucose monitoring system that beneficiaries will use twice a day to calibrate the CGM. Per Medicare rules, the products had to be shipped together. That agreement was reached in early July.
Demand among beneficiaries is so high that 20,000 Medicare patients are currently in the pipeline for CGM before Dexcom has done any major promotion of the change of Medicare policy, spokeswoman Julia Yuryev said in an e-mail to The American Journal of Managed Care®.
In total, 800,000 seniors are eligible for CGM, including virtually all Medicare beneficiaries with type 1 diabetes (T1D), and those with type 2 diabetes (T2D) who are on intensive insulin therapy and have been performing blood glucose tests at least 4 times a day.
Yuryev said Dexcom has hired and trained a dedicated team of Medicare sales and support staff for beneficiaries who are assisting existing Dexcom CGM patients, following by new patients in the order their requests were received.
To be eligible for reimbursement, Medicare requires specific documentation from physicians in patient medical records. The following must be documented:
Failure to meet the criteria mean Medicare will not pay for the Dexcom G5 or the supplies, giving patients a strong incentive to have good adherence.
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
A global AIDS program that was in limbo for months got temporary relief after congressional negotiators agreed to a 1-year renewal in the next government funding package; the outcome of the November presidential election could determine the state of fetal tissue research in the US; federal officials and industry executives failed to make improvements that stop hacking attacks.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Fragmented Payer System, Vulnerable Supply Chain Among Threats to Accessing Essential Medicines
March 13th 2024During a session of the 2024 V-BID Summit, panelists Stacie Dusetzina, PhD, and Inma Hernandez, PharmD, PhD, discussed how access to essential medications is curtailed not just by the longstanding complexities of insurance design but also by emerging threats such as supply chain weaknesses and cyberattacks.
Read More
Most private health insurers have yet to publish criteria for when they will cover postpartum depression drug, zuranolone; state lawmakers are increasingly opposing health care mergers that they believe do not serve the public interest; Medicaid extensions made in 2021 led to a 40% decline in postpartum lack of insurance.
Read More